The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 randomized trial of neoadjuvant enoblituzumab versus standard of care in men with high-risk localized prostate cancer: The help elucidate and attack longitudinally (HEAT) prostate cancer randomized study.
 
Eugene Shenderov
Stock and Other Ownership Interests - LifeImmune
Consulting or Advisory Role - GT Biopharma; PATHAI
Research Funding - AstraZeneca (Inst); Macrogenics (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending in field of allergy immunology and blood diagnostics
 
Angelo M De Marzo
No Relationships to Disclose
 
Tamara L. Lotan
Consulting or Advisory Role - Janssen Oncology
Research Funding - AIRA Matrix (Inst); DeepBio; Exact Sciences; Ventana Medical Systems
 
Hao Wang
No Relationships to Disclose
 
Edward M. Schaeffer
Consulting or Advisory Role - Abbvie; Lantheus Medical Imaging; Pfizer
 
Maha H. A. Hussain
Honoraria - Academic CME; AstraZeneca; AstraZeneca; Bayer; Bayer; Clinical Care Options; Great Debates and Updates; Medscape; Merck; Novartis; Research to Practice; Targeted Oncology
Consulting or Advisory Role - AstraZeneca; Bayer; Bayer; Convergent Therapeutics; GlaxoSmithKline; GlaxoSmithKline; Janssen; Merck; Novartis; Novartis; Pfizer; Tango Therapeutics; Tempus
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
Travel, Accommodations, Expenses - Bayer
 
Oliver Sartor
No Relationships to Disclose
 
Paras H Shah
No Relationships to Disclose
 
Ximing J Yang
No Relationships to Disclose
 
Paari J. Murugan
No Relationships to Disclose
 
Sounak Gupta
No Relationships to Disclose
 
Christopher Warlick
No Relationships to Disclose
 
Stephen A. Boorjian
Consulting or Advisory Role - ArTara Therapeutics; Ferring; Prokarium
 
Ashley Ross
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Blue Earth Diagnostics; Decipher Biosciences; Janssen Biotech; Lantheus Medical Imaging; Myovant Sciences; tempus
Consulting or Advisory Role - Astellas Pharma; BillionToOne
Speakers' Bureau - Tempus
 
Christian P. Pavlovich
No Relationships to Disclose
 
Emmanuel S. Antonarakis
Consulting or Advisory Role - AADi; AIkido Pharma; Amgen; AstraZeneca; Bayer (Inst); Blue Earth Diagnostics; Corcept Therapeutics; Curium Pharma; Foundation Medicine; Hookipa Pharma; Janssen Biotech; Lilly; Menarini Silicon Biosystems; Merck; Pfizer; Sanofi; Tango Therapeutics; Tempus; Z-Alpha
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Macrogenics (Inst); Merck (Inst); Orion Health (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
 
Mohamad E. Allaf
No Relationships to Disclose